Tag Archive for: Series A

Actithera Raises $75.5M in Oversubscribed Series A Financing to Redefine Precision Radioligand Therapy

/in

Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndicate including Bioqube Ventures, Surveyor Capital and others Led by founder and drug discovery expert Dr. Andreas Goutopoulos, Actithera’s proprietary three-pillar discovery platform is designed to enable prolonged radioligand tumor retention  Proceeds will support clinical […]

Read more

Bioptimus Hits $76M Funding Milestone and Prepares to Launch Groundbreaking Foundation Model for Biology

/in

Bioptimus announces a $76M funding milestone, with the latest injection of $41M led by Cathay Innovation less than 12 months from its initial seed round Since the successful release of the largest AI foundation model for pathology in July, the company has been continuing its groundbreaking work and is now poised to release a breakthrough […]

Read more

Women’s Health Company Freya Biosciences Announces Key $10.4 Million Strategic Investment

/in

Strategic investment from the Bill & Melinda Gates Foundation with additional investment from EIFO brings the total to $11.8 million The new investment extends Series A investment to about $50 million Funds will be used to expand Freya’s DYSCOVERTM platform to identify and develop microbial immunotherapies to treat bacterial vaginosis and prevent pre-term birth COPENHAGEN, Denmark and BOSTON, Nov. 19, 2024 /PRNewswire/ — Freya […]

Read more

Precision oncology company Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors

/in

V-Bio Ventures leads international syndicate which includes Johnson & Johnson Innovation – JJDC, Inc., QBIC Fund, Flanders Future Tech Fund, Curie Capital as well as seed investors Oncode Oncology Bridge Fund, Swanbridge and BOM Flindr discovers and develops precision oncology therapeutics with the potential to eradicate tumors in specific patient populations Lead asset is a […]

Read more

Novo Holdings Joins €30M Series A Financing for Asgard Therapeutics, Leader In In Vivo Cell Reprogramming To Treat Cancer

/in

Financing to advance first platform designed to reprogram cancer cells into immune cells as pan-tumoral cancer treatment Novo Holdings participation follows earlier investment and incubation through seed phase Financing co-led by RV Invest and Johnson & Johnson Innovation, joined by existing investors Boehringer Ingelheim Venture Fund and Industrifonden COPENHAGEN – March 14th, 2024 – Novo Holdings, […]

Read more